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Abstract
Background: The development and spread of drug resistant Plasmodium falciparum strains is a major concern and
novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven
anti-malarial activity against chloroquine-resistant and -sensitive P. falciparum laboratory strains.
Methods: Adult young male aged 18 to 45 years, asymptomatic carriers of P. falciparum, were included in two-
dose escalation, double-blind, randomized, placebo-controlled Phase I trials, a single dose study and a multiple
dose study aiming to evaluate oral doses of ferroquine from 400 to 1,600 mg.
Results: Overall, 54/66 patients (40 and 26 treated in the single and multiple dose studies, respectively)
experienced at least one adverse event, 15 were under placebo. Adverse events were mainly gastrointestinal
symptoms such as abdominal pain (16), diarrhoea (5), nausea (13), and vomiting (9), but also headache (11), and
dizziness (5). A few patients had slightly elevated liver parameters (10/66) including two patients under placebo.
Moderate changes in QTc and morphological changes in T waves were observed in the course of the study.
However, no adverse cardiac effects with clinical relevance were observed.
Conclusions: These phase I trials showed that clinically, ferroquine was generally well-tolerated up to 1,600 mg as
single dose and up to 800 mg as repeated dose in asymptomatic young male with P. falciparum infection. Further
clinical development of ferroquine, either alone or in combination with another anti-malarial, is highly warranted
and currently underway.
Background
Plasmodium falciparum has become resistant to several
commonly used anti-malarial drugs. As a consequence
new anti-malarial compounds are urgently needed.
Despite a considerable increase in international efforts
in anti-malarial drug development, there is at present a
shortage of truly novel drugs which do not share the
same mechanisms of action and drug resistance with
those that are failing today. The entire reliance on arte-
misinin derivatives in the drug development over the
past decade might be deceptive in the light of first
reports of artemisinin resistant P. falciparum [1].
Ferroquine (SSR97193) - a ferrocenic derivative of
chloroquine and thus a 4-aminoquinoline compound -
is a truly novel anti-malarial candidate drug. Ferro-
quine demonstrated anti-malarial activity in vitro and
in vivo [2-5]. In vitro, ferroquine has a potent activity
on Plasmodium falciparum laboratory strains, whether
they are sensitive or resistant to chloroquine. In vivo,
four days of treatment with ferroquine efficiently cured
mice infected with either chloroquine-resistant or sen-
sitive strains of Plasmodium vinckei. Ferroquine is a
racemic compound with both enantiomers showing an
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pound, in vitro and in vivo. Ferroquine is metabolized
into one major metabolite (N-monodemethylated), also
highly active in vitro. Tests on field isolates confirmed
the activity of ferroquine against parasites that are
multi-resistant to most marketed anti-malarial agents
and did not show any significant cross sensitivity with
major anti-malarials currently used [5-8].
Preclinical studies
Ferroquine was tested in preclinical studies prior to its use
in humans, alone or in combination with artesunate,
showing it to be devoid of relevant adverse effects on cen-
tral nervous system, respiratory, renal, and gastrointestinal
functions. The only notable effects of ferroquine alone, or
in combination with artesunate, were observed on cardio-
vascular function. In vitro ferroquine, at a high concentra-
tion, was shown to affect the action potential pattern as a
result of human ether-à-go-go related gene (hERG) chan-
nel inhibition (inhibitory concentration decreasing a
response by 50% (IC50) = 907 ng/mL). In vivo, in anaes-
thetized but not in conscious dogs, ferroquine induced
from blood concentrations ≥200 ng/mL major haemody-
namic effects. In vivo, in conscious dogs, a ferroquine/arte-
sunate combination (at 30 mg/kg and 100 mg/kg per os,
respectively, i.e., ferroquine blood concentrations of 669
ng/mL) was devoid of effects on blood pressure, heart
rate, PR interval, and QRS complex duration whereas
QTcB and QTcF were slightly increased [artesunate alone
had no significant effect on cardiovascular and electrocar-
diogram parameters]. However, no increases in QT, QTc
were noted in the 13-week oral toxicity study in dogs at
0.2/25, 1/25 and 5/25 mg/kg of ferroquine/artesunate
combination and at 5 mg/kg of ferroquine alone.
Previous human experience
First, in human studies of ferroquine were conducted in
a double-blind, randomized, placebo controlled, and
sequential dose escalation study in 42 healthy male sub-
jects in Germany [unpublished data]. Single oral doses
up to 800 mg were clinically well tolerated and no drug-
related clinically relevant adverse event was observed.
One serious adverse event occurred which was unrelated
to the study drug and all other adverse events were mild
to moderate and no relevant electrocardiogram abnorm-
alities, such as QT prolongation or repolarisation
abnormalities were described.
This is a report on two clinical phase I trials, which
aimed to assess the clinical, and laboratory safety and
tolerability profile of ferroquine. These studies were
designed to evaluate ascending oral doses in young male
volunteers with asymptomatic P. falciparum infection
and to determine the maximum tolerated dose after oral
administration of ferroquine.
Methods
Study design, settings and population
Both clinical trials were designed as phase I, rando-
mized, double blind, placebo-controlled, sequential dose
escalation studies. The first study TDU5967 (“Single
Dose Study”) was designed as a dose escalation trial of a
single oral dose, whereas the second study TDR5969 (“3
Day Repeated Dose Study”) aimed to evaluate a three-
day treatment course.
Clinical work was carried out from April 2005 to June
2006 at the Medical Research Unit of the Albert
Schweitzer Hospital in Lambaréné, Gabon, a semi-urban
town of about 30,000 inhabitants where malaria trans-
mission is perennial with moderate seasonal variation
[9,10].
Male volunteers aged between 18 and 45 years resid-
ing in Lambaréné and its surrounding areas were invited
to participate. Individuals having provided written
informed consent and harbouring asymptomatic
P. falciparum infection were enrolled into the study if
they fulfilled the following criteria: (1) weight between
50 and 90 kg, (2) BMI of 18 to 28 kg/m
2,( 3 )n o r m a l
vital signs after 10 minutes resting in supine position,
i.e. systolic blood pressure between 95 and 140 mmHg,
and diastolic blood pressure between 50 and 90 mmHg,
and heart rate between 45 and 90 beats per minute,
(4) normal 12-lead automatic ECG, (5) and no fever or
history of fever in the last 72 hours. Exclusion criteria
were (1) presence of any clinical signs of malaria,
(2) previous anti-malarial treatment, (3) significant co-
morbidities or other conditions impeding compliance
with the study, (4) presence or history of drug allergy,
(5) evidence for hepatitis B, C, or HIV infection (HBs
antigen, anti-HCV antibodies, anti-HIV1&2 antibodies).
The studies were granted ethical clearance by the
Ethics Committee of the International Foundation of the
Albert Schweitzer Hospital. The study protocols com-
plied with recommendations of the 18
th World Health
Congress (Helsinki, 1964) and all applicable amend-
ments, also with laws, regulations, and any applicable
guideline of Gabon, the country where the studies were
conducted in compliance with the International Harmo-
nized Conference on Good Clinical Practices guidelines.
Informed consent was obtained prior to the conduct of
any study-related procedures.
Interventions
Randomization and blinding
Study treatments were prepared by dose level for each
patient according to the study randomization list. The
following doses of ferroquine were to be explored,
400 mg, 800 mg, 1,200 mg, 1,400 mg, and 1,600 mg for
the single dose study and 400 mg, 600 mg, 800 mg, and
1,000 mg for the three-day repeated dose study.
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groups of eight participants per dose group. Six partici-
pants were to receive ferroquine and two participants
were to receive placebo. All ferroquine dose strengths
and placebo capsules were identically matched. The first
patients were assigned to the lowest dose level of the
study.
The treatment allocation was double-blinded and was
done according to the randomization list which was
computer-generated. The allocation code was concealed
at site and procedures were put in place to have the
option for code breaking in case of urgent clinical need.
Decision for dose escalation was based on a thorough
review of clinical and laboratory data, including ECG
and pharmacokinetic data of the preceding dose level.
Study procedures
Screening and drug administration
Recruitment of volunteers was started with a pre-screen-
ing visit to determine the P. falciparum infection status
by blood smear, Rapid Test and PCR [11]. If infection
was confirmed by at least one out of these three labora-
tory tests, the volunteers were invited to undergo
screening procedure, including a complete physical
examination, haematology and biochemistry analysis,
urinalysis, urine drug screen, and viral serology (HIV,
HBSAg, HCV). Eligible volunteers were admitted as
inpatients to the Medical Research Unit and study drugs
were administered orally with noncarbonated water
under fasted conditions. Treatment duration was one
day in the single dose study and three days in the multi-
ple dose study. Volunteers were discharged from the
hospital two days after the last drug intake and were
followed-up for eight weeks in both studies.
Recording and reporting of adverse events and cardiac
effects
Adverse events were defined as any clinical change from
baseline or previous visit spontaneously reported by the
patient or observed by the investigator. All adverse
events regardless of seriousness or relationship to the
investigational product were recorded. Adverse events
were coded according to Medical Dictionary for regula-
tory Activities (MedDRA, version 8.1).
Due to the very long half-life of the product, around
20 days, the rule applied for the emergence of adverse
event was 5 half-lives after administration. Thus, an
adverse event was considered as emergent until the end-
of-study visit. Abnormalities of vital signs, laboratory
parameters or ECG readings were recorded as adverse
events only if they were medically relevant by being
symptomatic, requiring corrective treatment, leading to
discontinuation and/or fulfilling a seriousness criterion.
A standard 12-lead ECG was performed hourly up to
six hours post-dosing, two-hourly up to 12 hours post-
dose, and weekly until the end of follow-up. ECG mea-
sures were obtained from measurement of three conse-
cutive QRS complexes and averaged. Heart rates, QTc
(Bazett and Fridericia) were derived from the mean
values of the measured parameters. In addition, a 24-hr
ECG was recorded in the repeated dose study for five
days to detect cardiac rhythm abnormalities.
Outcomes and statistics
Primary outcomes (endpoints) for these randomized
clinical trials were defined as the clinical and laboratory
adverse event profile and the effect of ferroquine on the
cardiovascular system.
Sample size for these studies was based upon empiri-
cal considerations from clinical phase I studies and no
formal sample size calculation was performed. Safety
analysis was based on participants who were adminis-
tered at least one dose of study drug (exposed popula-
tion) including participants who withdrew consent
prematurely. If a participant had received the study drug
and prematurely stopped study participation he was
replaced, unless if follow up data were available up to
day 15.
Results
Study population
Out of a total of 498 volunteers pre-screened, 158 per-
sons with P. falciparum infections were further screened
for eligibility. Eighty-four were excluded because of
abnormal chemistry or haematology results, abnormal
ECGs, or other health problems. Seventeen volunteers
could not be enrolled due to logistical reasons and
further eight volunteers were not enrolled because the
predefined number of participants for each of the two
studies was already reached. Recruitment and partici-
pant flow are depicted in Figure 1.
A total of 66 asymptomatic male volunteers infected
with P. falciparum were enrolled, randomized, and
treated. In the single dose study, a total of 30 volun-
teers were exposed to single oral doses of ferroquine
over a range from 400 mg to 1,600 mg and 10 received
placebo. In the three-day multiple dose study, 19
volunteers were treated for three days with daily doses
from 400 mg to 1,000 mg and seven received placebo.
Only one participant was administered the 1,000 mg
dose. Enrolment was discontinued at 1,000 mg dose
because of morphologic changes in T waves and a
moderate QT prolongation observed in patients treated
with 800 mg and 1,000 mg. Seven participants stopped
the study prematurely for reasons unrelated to adverse
events, three in the single dose study and four in the
three-day repeated dose study (Figure 1). Baseline
characteristics of study participants are provided in
Table 1 and Table 2.
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Details on the frequency of adverse events by dose-group
are depicted in Table 3 and Table 4. In the single, ascend-
ing dose study, most patients in the placebo group (9/10)
presented at least one adverse event during the study
versus 3/6 patients in the 400 m dose group, 1/6 in the
800 mg dose group, 6/6 in the 1,200 mg and 1,400 mg
dose groups, and 4/6 patients in the 1,600 mg dose group.
In the three-day repeated, ascending dose study, six
patients out of seven in the placebo group experienced at
   498 Volunteers pre-screened for presence of 
Plasmodium falciparum 
Excluded: 340  
x  Non-infected 254   
x  Refused to continue  44 
x  lost contact 42 
   151 Volunteers infected 
with Plasmodium falciparum 
screened for eligibility 
 
   
   
 
Single dose study   
40 participants enrolled and randomized 
800 mg Single Dose (N=8 randomized) 
- 6 participants received 8 FQ capsules 
- 2 participants received 8 placebo matched capsules 
400 mg Single Dose (N=8 randomized) 
- 6 participants received 4 FQ capsules 
- 2 participants received 4 placebo matched capsules 
1200 mg Single Dose (N=8 randomized) 
- 6 participants received 12 FQ capsules 
- 2 participants received 12 placebo matched capsules 
1400 mg Single Dose (N=8 randomized) 
- 6 participants received 14 FQ capsules 
- 2 participants received 14 placebo matched capsules 
Repeated dose study   
26 participants enrolled and randomized 
400 mg 3-Day Repeated Dose (N=8 randomized) 
- 6 participants received 2 FQ capsules 
- 2 participants received 2 placebo matched 
capsules 
600 mg 3-Day Repeated Dose (N=8 randomized) 
- 6 participants received 3 FQ capsules 
- 2 participants received 3 placebo matched 
capsules 
800 mg 3 Day Repeated Dose (N=8 randomized) 
- 6 participants received 4 FQ capsules 
- 2 participants received 4 placebo matched 
capsules 
1000 mg 3 Day Repeated Dose (N=2 randomized) 
- 1 participant received 5 FQ capsules 
- 1 participant received 5 placebo matched capsules 
  1600 mg Single Dose (N=8 randomized) 
- 6 participants received 16 FQ capsules 
- 2 participants received 16 placebo 
matched capsules 
  Discontinued Follow up: 1 FQ (Poor compliance, Day 16) 
     1 placebo (Migration, Day 58) 
  Discontinued Follow up: 1 FQ (Migration, Day 48) 
  Discontinued Follow up: 1 FQ (Migration, Day 6) 
Discontinued Follow up: 1 FQ (Patient request, Day 21) 
  Discontinued Follow up: 1 FQ (Patient request, Day 36) 
Discontinued Follow up: 1 FQ (Lost to Follow-up, Day 53) 
  Excluded: 84 
-  Abnormal chemistry or hematology 8 
-  HIV positive 6 
-  HbsAg positive 15 
-  HCV positive 4 
-  Abnormal ECG 1 
-  Refused to participate 9 
-  Scheduling conflict 8 
-  lost contact 12 
-  Other reasons: 21 
Eligible but not enrolled: 08 
Figure 1 Flow of participants.
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Page 4 of 11least one adverse event during the trial versus all of the
subjects taking ferroquine (19/19). The adverse events
reported were mainly in the gastrointestinal tract, abdom-
inal pain (16), diarrhoea (5), nausea (13), vomiting (9) and
toothache (6), and in the nervous system disorders,
headache (11) and dizziness (5), but also those that
appeared during the follow-up period, in the musculoske-
letal and connective tissue disorders (9), such as arthralgia
and back pain, the injury, poisoning and procedural com-
plications (10) (injury, post-traumatic pain, thermal burn).
Table 1 Demographic and clinical characteristics of participants at baseline in the single dose study
Parameters
(Unit)
Statistics/
Category
Single Dose Study
Placebo Ferroquine
(N = 10) 400 mg (N = 6) 800 mg (N = 6) 1200 mg (N = 6) 1400 mg (N = 6) 1600 mg (N = 6)
Age (years) Mean (SD) 30.5 (9.4) 32.0 (4.4) 31.2 (6.1) 30.5 (8.8) 24.3 (6.3) 26.5 (4.0)
Min - Max 18 - 44 27 - 37 22 - 38 20 - 42 18 - 34 19 - 30
Height (cm) Mean (SD) 167.3 (8.7) 168.8 (7.0) 168.7 (3.9) 166.2 (7.4) 172.7 (6.7) 164.3 (5.0)
Min - Max 147 - 176 160-176 163-174 154-174 163 - 183 157 - 172
Weight (kg) Mean (SD) 66.0 (7.8) 62.8 (9.3) 64.7 (3.6) 62.7 (8.5) 65.2 (3.5) 60.6 (5.2)
Min - Max 55 - 78 50-71 58-59 52-75 61 - 70 57 - 71
BMI (kg/m
2) Mean (SD) 23.59 (2.40) 21.92 (1.85) 22.77 (1.61) 22.65 (1.83) 21.92 (1.25) 22.48 (0.88)
Min - Max 20.1-27.6 19.5-24.3 19.8-24.5 19.6-24.8 19.7 - 23.0 21.9 - 24.0
BSA (m
2) Mean (SD) 1.74 (0.14) 1.72 (0.16) 1.74 (0.05) 1.70 (0.15) 1.74 (0.14) 1.78 (0.08)
Min - Max 1.5 - 1.9 1.5 - 1.8 1.7 - 1.8 1.5 - 1.9 1.5 - 1.9 1.7 - 1.9
HR (bpm) Mean (SD) 50.9 (6.9) 56.3 (3.7) 54.4 (5.9) 53.3 (9.3) 56.8 (6.6) 54.6 (9.3)
Min - Max 42 - 67 51 - 61 46 - 63 41 - 62 47 - 66 44 - 66
QTc B (ms) Mean (SD) 374.7 (19.6) 378.9 (20.6) 374.0 (11) 368.3 (16.9) 369.4 (28.9) 371.3 (20.6)
Min - Max 347 - 405 346 - 405 362 - 392 337 - 388 327 - 408 334 - 396
QTc F (ms) Mean (SD) 386.5 (22.1) 384.0 (19.3) 380.5 (9.3) 376.9 (13.5) 373.4 (26.7) 378.4 (20.8)
Min - Max 357 - 416 350 - 403 363 - 389 356 - 391 341 - 416 353 - 409
NOTE: BMI: Body Mass Index; BSA: Body Surface Area; HR: Heart Rate; QTc (Bazett Fridericia); N: Count of patients; SD: standard deviation; Min: minimum; Max:
maximum.
Table 2 Demographic and clinical characteristics of participants at baseline in the multiple dose study
Parameters (Unit) Statistics/Category Multiple Dose Study
Placebo Ferroquine
(N = 7) 400 mg (N = 6) 600 mg (N = 6) 800 mg (N = 6) 1000 mg (N = 1)
Age (years) Mean (SD) 23.6 (5.3) 30.2 (6.2) 26.2 (6.3) 24.5 (5.8) NA
Min - Max 18 - 33 25 - 40 18 - 35 19 - 32
Height (cm) Mean (SD) 168.6 (6.5) 167.5 (5.8) 166.5 (10.5) 170.8 (9.9) NA
Min - Max 160 - 178 158 - 173 150 - 181 155 - 184
Weight (kg) Mean (SD) 63.0 (2.6) 64.8 (8.3) 59.8 (10.1) 61.3 (5.0) NA
Min - Max 59 - 66 55 - 75 50 - 74 56 - 70
BMI (kg/m
2) Mean (SD) 22.24 (1.61) 23.03 (1.74) 21.48 (1.97) 21.05 (1.19) NA
Min - Max 20.5 - 25.0 21.3 - 25.3 19.2 - 24.5 19.8 - 23.3
BSA (m
2) Mean (SD) 1.67 (0.09) 1.73 (0.13) 1.66 (0.19) 1.72 (0.13) NA
Min - Max 1.6 - 1.8 1.5 - 1.9 1.4 - 1.9 1.5 - 1.9
HR (bpm) Mean (SD) 53.8 (6.9) 59.2 (7.8) 55.6 (3.7) 52.9 (1.2) NA
Min - Max 48 - 63 52 - 72 51 - 60 48 - 62
QTc B (ms) Mean (SD) 366.6 (11) 380.7 (15.7) 359.0 (21.8) 373.8 (24) NA
Min - Max 358 - 384 367 - 409 150 - 181 340 - 406
QTc F (ms) Mean (SD) 373,9 (6.3) 382.0 (11.7) 362.8 (22.5) 381.2 (24.5) NA
Min - Max 368 - 382 372 - 403 335 - 404 340 - 399
NOTE: BMI: Body Mass Index; BSA: Body Surface Area; HR: Heart Rate; QTc (Bazett Fridericia); N: Count of patients; SD: standard deviation; Min: minimum; Max:
maximum.
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(blurred vision, floating objects), mild skin rash (ECGs
electrode application sites dermatitis or pruritis), infec-
tions and infestations, and fatigue were infrequent and
were single occurrences across all dose groups in either
study. All adverse events were considered mild to mod-
erate in intensity and were transient. There were no
deaths, serious adverse events, or adverse events leading
to withdrawal reported during the trials.
Because of the small numbers of volunteers studied at
each dose, no significant conclusions can be drawn from
comparisons of adverse events between dose groups at
the individual dose levels.
Clinical laboratory evaluation
The clinical laboratory evaluation was performed
through clinical chemistry and haematology tests of
samples taken at different time points of scheduled visits
until the end-of-study visit (60 days). The majority of
the clinical chemistry potentially clinically significant
abnormalities observed on patients treated with con-
cerned elevations of creatine phosphokinase (≥3U L N ,
normal range 25-90 IU). In most cases, creatine phos-
phokinase was elevated at baseline and was related to
intense farming activities prior to inclusion (Table 5 and
Table 6).
In the single dose study, five patients out of 40 showed
an alanine transaminase increase >1 ULN (defined as 45
I U / m l )a ta n yt i m ep o i n to ft h es t u d yw i t hap o s s i b l e
association to changes of other liver functions. Among
them were four patients treated with ferroquine and one
patient treated with placebo. These changes were asymp-
tomatic and, therefore, were not reported as adverse
events. One patient under placebo experienced an
increased level of alanine transaminase, with a maximum
value of 59 IU on Day 21. The increase was associated to
Table 3 Frequency of the most common adverse events during the single dose study
System organ class Preferred term Single Dose Study
Placebo Ferroquine
(N = 10) 400 mg
(N = 6)
800 mg
(N = 6)
1200 mg
(N = 6)
1400 mg
(N = 6)
1600 mg
(N = 6)
Any class Any TEAE 9 (90) 3 (50) 1 (17) 6 (100) 6 (100) 4 (67)
Gastrointestinal disorders Any TEAE 4 (40) 0 0 3 (50) 4 (67) 4 (67)
Abdominal pain 3 (30) 0 0 0 3 (50) 2 (33)
Diarrhoea 0 0 0 1 (17) 2 (33) 0
Nausea 1 (10) 0 0 1 (17) 1 (17) 2 (33)
Toothache 1 (10) 0 0 1 (17) 0 0
Vomiting 0 0 0 1 (17) 1 (17) 2 (33)
Nervous system disorders Any TEAE 2 (20) 0 0 3 (50) 1 (17) 3 (50)
Dizziness 1 (10) 0 0 0 1 (17) 2 (33)
Headache 1 (10) 0 0 3 (50) 1 (17) 1 (17)
NOTE: N (%): count of patients (percentage per group); TEAE: treatment emergent adverse event.
Table 4 Frequency of the most common adverse events during the multiple dose study
System organ class Preferred term Multiple Dose Study
Placebo Ferroquine
(N = 7) 400 mg (N = 6) 600 mg (N = 6) 800 mg (N = 6) 1000 mg (N = 1)
Any class Any TEAE 6 (86) 6 (100) 6 (100) 6 (100) 1 (100)
Gastrointestinal disorders Any TEAE 4 (57) 3 (50) 4 (67) 5 (83) 1 (100)
Abdominal pain 3 (43) 1 (17) 1 (17) 2 (33) 1 (100)
Diarrhoea 0 0 0 2 (33) 0
Nausea 1 (14) 2 (33) 2 (33) 3 (50) 0
Toothache 1 (14) 1 (17) 0 2 (33) 0
Vomiting 0 1 (17) 2 (33) 1 (17) 1 (100)
system disorders Any TEAE 1 (14) 1 (17) 3 (50) 1 (17) 0
Dizziness 0 0 1 (17) 0 0
Headache 1 (14) 1 (17) 2 (33) 1 (17) 0
NOTE: N (%): count of patients (percentage per group); TEAE: treatment emergent adverse event.
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Page 6 of 11Table 5 Summary of participants with PCSA (parameters with PCSA definitions) for clinical chemistry and haematology parameters during the single dose
study
Laboratory blood parameters (PCSA definition) Normal range Single Dose Study
Placebo Ferroquine
(N = 10) 400 mg (N = 6) 800 mg (N = 6) 1200 mg (N = 6) 1400 mg (N = 6) 1600 mg (N = 6)
Eosinophils (> max (0.5 Giga/L, ULN)) 0-1320/μl 6 5 1 365
Haemoglobin (decrease≥ 2 g/dL versus baseline) 10.0-16.5 g/dL 1 0 4 1 0 0
Neutrophils (<1.0 Giga/L, Black) 1400-8140/μL 4 3 2 114
Platelets (<100 Giga/L) 120-400 Giga/L 0 0 0 0 0 0
White Blood Cells (<2 Giga/L, Black) 3.5-11/μL 0 1 1 000
ALT (PCSA >2 ULN) < 45 U/L 0 1 1 0 0 0
AST (PCSA >2 ULN) < 45 U/L 0 1 1 0 0 2
Alkaline phosphatase (>1.5 ULN) 13 - 100 U/L 0 0 1 0 0 0
CPK (≥ 3U L N ) 25-90 U/L 1 0 2 2 1 1
Creatinine (≥ 150 μmol/L, adults) <133 μmol/L 1 0 1 0 0 1
Gamma GT (≥ 3 ULN) <50 U/L 0 0 1 0 0 0
Glucose (≤ 2.5 mmol/L) 3.6-6.1 mmol/L 0 0 0 0 1 1
Glucose (≥ 2 mmol/L, fasted) 3.6-6.1 mmol/L 1 0 0 0 0 0
Potassium (< 3 mmol/L) 3.5-5.0 mmol/L 0 1 0 0 0 0
Potassium (≥ 5.5 mmol/L) 3.5-5.0 mmol/L 0 0 0 0 1 1
Total bilirubin (≥ 34 μmol/L) 0-17 μmol/L 1 1 0 0 0 0
Total cholesterol (≥ 7.74 mmol/L) 120-240 mg/dL 0 0 0 0 0 0
Triglycerides (≥ 4.6 mmol/L) 0-200 mg/dL 0 0 0 0 0 0
NOTE: N: count of patients; PCSA: Potentially Clinically Significant Abnormality (version 2.2, December 2004); LLN/ULN: Lower/Upper Limit of Normality. For hemoglobin, baseline values <LLN or >ULN are counted
normal; for eosinophils, values <LLN are counted as normal. For ALT, AST, ALP, Total Bilirubin, GGT, CPK, baseline values <LLN are counted normal.
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1a parallel and moderate increase of total bilirubin (19
μmol/L, normal range <17 μmol/L) and a moderate
increase of aspartate transaminase and gamma glutamyl
transferase. In the 800 mg dose-group, one patient had
an increased level of alanine transaminase with a maxi-
mum value of 148 IU on Day 15, with associated
increases in total bilirubin (24 μmol/L), aspartate transa-
minases, alkaline phosphatases, and gamma glutamyl
transferase. In the 1,200 mg dose-group, at one patient
an increased level of alanine transaminase with a maxi-
mum value of 52 IU was observed on Day 7, whereas,
alkaline phosphatase and total bilirubin (5 μmol/L)
remained within normal ranges. At one patient treated
with 1,400 mg, an increased level of alanine transaminase
with a maximum value of 47 IU was observed on Day 15,
associated to parallel changes in other liver function
parameters at the exception of the bilirubin level (8
μmol/L). Finally, one patient was one of the 1,600 mg
dose-group experienced an increase of alanine transami-
nase values with a maximum value of 48 IU on Day 2
with parallel increase in total bilirubin (25 μmol/L) on
Day 15. The respective parameters of this patient were
already slightly elevated at baseline (Day -1).
In the three-day repeated dose study, elevated alanine
transaminases (>2 ULN) was observed in one placebo-
treated patient and in four patients in the ferroquine
groups. One patient in the 400 mg group (normal base-
line 0.38 ULN) had an alanine transaminase >10 ULN
starting at Day 12 with a maximum magnitude of 16.55
ULN, which was associated to abdominal pain and head-
ache. Over the course of the following week, alkaline
phosphatases and bilirubin increased and picked at
about 2 ULN and 1.7 ULN, respectively. Infectious
causes were ruled out. However, the patient reported
intake of an herbal tea against abdominal pain, which
might have contributed to the enzyme abnormalities.
Alanine transaminases returned to normal by Day 37
(0.71 ULN). A patient of the 600 mg group, who had a
slightly elevated alanine transaminase value at screening
(1.22 ULN), but within normal ranges at baseline (0.91
ULN), presented again an elevated value on Day 3 (1.71
ULN) and reached the potentially clinically significant
abnormality level (2.18 ULN) on Day 5, subsequently
followed by a decrease to normal rangeby Day 12. In
this same 600 mg dose group, another patient with nor-
mal baseline value of 0.42 ULN, presented an elevated
Table 6 Summary of participants with PCSA (parameters with PCSA definitions) for clinical chemistry and haematology
parameters during the multiple dose study
Laboratory blood parameters (PCSA definition) Normal range Multiple Dose Study
Placebo Ferroquine
(N = 7) 400 mg
(N = 6)
600 mg
(N = 6)
800 mg
(N = 6)
1000 mg
(N = 1)
Eosinophils (> max (0.5 Giga/L, ULN)) 0-1320/μl4 2 4 4 1
Haemoglobin (decrease≥ 2 g/dL versus baseline) 10.0-16.5 g/dL 0 0 0 0 0
Neutrophils (<1.0 Giga/L, Black) 1400-8140/μL03020
Platelets (<100 Giga/L) 120-400 Giga/L 1 1 2 0 0
White Blood Cells (<2 Giga/L, Black) 3.5-11/μL0 1 0 0 0
ALT (normal <45UI, PCSA >2 ULN) < 45 U/L 1 1 2 1 0
AST (normal <45UI, PCSA >2 ULN) < 45 U/L 1 1 0 1 0
Alkaline phosphatase (>1.5 ULN) 13 - 100 U/L 0 1 0 1 0
CPK (≥ 3 ULN) 25-90 U/L 3 4 5 5 1
Creatinine (≥ 150 μmol/L, adults) <133 μmol/L 0 1 0 0 0
Gamma GT (≥ 3 ULN) <50 U/L 0 1 0 1 0
Glucose (≤ 2.5 mmol/L) 3.6-6.1 mmol/L 0 0 0 0 0
Glucose (≥ 2 mmol/L, fasted) 3.6-6.1 mmol/L 0 0 0 0 0
Potassium (< 3 mmol/L) 3.5-5.0 mmol/L 0 0 0 0 0
Potassium (≥ 5.5 mmol/L) 3.5-5.0 mmol/L 2 0 2 0 0
Total bilirubin (≥ 34 μmol/L) 0-17 μmol/L 1 1 0 0 0
Total cholesterol (≥ 7.74 mmol/L) 120-240 mg/dL 0 0 0 0 0
Triglycerides (≥ 4.6 mmol/L) 0-200 mg/dL 0 0 0 0 0
NOTE: N: count of patients; PCSA: Potentially Clinically Significant Abnormality (version 2.2, December 2004); LLN/ULN: Lower/Upper Limit of Normality. For
hemoglobin, baseline values <LLN or >ULN are counted normal; for eosinophils, values <LLN are counted as normal. For ALT, AST, ALP, Total Bilirubin, GGT, CPK,
baseline values <LLN are counted normal.
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Page 8 of 11alanine transaminase values on Day 3 that reached the
potentially clinically significant abnormality level on Day
23 (2.56 ULN). His values were still elevated at the end-
of-study visit (1.78 ULN). Finally, one patient of the
800 mg dose group, with normal baseline value of 0.38
ULN, had a peak alanine transaminases value of 6.37
ULN and a bilirubin value of 1.48 ULN at Day 12 with-
out clinical symptoms. Alkaline phosphatases peaked at
1.77 ULN on Day 17. Liver parameter values decreased
t o w a r dt h en o r m a lr a n g eb yt h ee n d - o f - s t u d yv i s i t .T h e
most frequently observed haematology, potencially clini-
cally significant abnormalities were related to eosino-
phils that were likely to be related to concomitant
parasitic infections existing at baseline.
Electrocardiogram evaluation
I nt h es i n g l ed o s es t u d y ,n oQ T c Fv a l u e s> 4 5 0m s ,o r
delta QTcF >60 ms were observed in any treatment
group. One patient in the 1,200 mg dose group experi-
enced a delta QTcF value between 30 and 60 ms, while
a moderate change in mean increases from baseline of +
8.2 ms was observed for the 1,600 mg dose level coin-
ciding with the time of maximal plasma concentrations.
In the three-day repeated dose study, continuous moni-
toring did not show any clinically significant arrhythmic
episode developing after drug administration in any
patient. A deviation in the repolarization pattern (inver-
sion of T wave), visible from T5 upwards and lasting for
several hours, was observed in four patients of the 800
mg dose group, especially in one patient who showed a
clear and long-lasting T inversion each day of investiga-
tional product administration. According to previous
experiences and the known influence of aminoquino-
lines on ECGs, these episodes were considered to be
related to the investigational product, but remained
without any clinical significance. In the 800 mg dose
group, there were 12.6 ms, 16.8 ms, and 19.2 ms mean
increases in QTcF intervals on Day 3 at 6, 8, and 12
hours, respectively. Additionally, in the 800 mg dose
group, there was a 19.6 ± 6.8 ms (mean ± SEM) maxi-
mum mean increase in QTcF intervals, compared to
maximum mean increases of 9.9 ± 5.5, 5.2 ± 3.6, and
16.5 ± 6.8 ms for the placebo, 400 mg, and 600 mg
groups, respectively. There were no delta QTcF intervals
>60 ms and no QTcF intervals >450 ms.
Discussion
Despite an increase in international investment in anti-
malarial drug development in the past decade only a few
novel drugs have been developed [12-19]. Ferroquine is
one of the few novel anti-malarials entering clinical
development. A favourable safety and tolerability profile
of ferroquine could be demonstrated when administered
a sas i n g l ed o s eu pt o1 , 6 0 0m go ra st h r e ec o n s e c u t i v e
daily doses up to 800 mg. No dose limiting clinical
adverse event was observed at the investigated dose
levels. All adverse events were mild to moderate, transi-
ent, and no serious drug related adverse event was
observed. These findings are in line with previous data of
preclinical studies and the first in human study per-
formed in healthy Caucasian subjects [unpublished data].
Gastrointestinal side effects and central nervous disor-
ders appear to be the most common clinical adverse
events following treatment with ferroquine. These symp-
toms were however self-limiting and mild to moderate
in intensity. Most important the frequency of these
events was similar in patients treated with ferroquine
and those receiving placebo and overall compared well
to currently used anti-malarials. However, these side
effects are well described for other 4-aminoquinoline
anti-malarials and need, therefore, further investigation
in the case of ferroquine [20-26]. Other less common
adverse events, such as fatigue, blurred vision and rash
were mild, transient, and were single occurrences across
all dose groups.
One limitation of the assessment of adverse events in
this study may be the potential progression of asympto-
matic infection to malaria. However, the inclusion of a
control group with placebo treatment helped to mini-
mize this factor in the absence of knowledge on the effi-
cacy of ferroquine in humans. Similarly, the apparent
dose dependent increase in gastrointestinal adverse
events may be either due to pharmacodynamic proper-
ties of the drug or alternatively to the high number of
capsules that had to be swallowed (up to 16 capsules
per participant). In summary, ferroquine may lead to
gastrointestinal side effects comparable to other anti-
malarials. However, the number of participants in this
study does not permit to make a final judgement on a
potential dose dependent increase of gastrointestinal
toxicity of ferroquine.
At eight weeks follow-up, there was no evidence for
cardiac, ocular, hepatic, haemotologic, renal, dermatolo-
gic, or other end-organ adverse events. Although
adverse events involving these and other organs have
been reported with aminoquinolines previously
[21,23-25], these findings have typically been observed
in persons treated for prolonged periods of time (more
t h a n5y e a r s )a td o s e s2 0 0 - 4 0 0m gb a s eo rh i g h e rp e r
day [21,27]. The absence of clinically significant detect-
able adverse events and the normal laboratory tests in
all volunteers at eight weeks of follow-up are consistent
with previous reports on the safety of short-term chloro-
quine treatment [20,21,26].
The finding of abnormal liver function tests in the
course of the study. These observations are consistent
with data from toxicology studies on rats and dogs
which showed small increases of alanine transaminase
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These changes were minor and not considered to be of
toxicological significance. In our clinical trials the
laboratory changes were not clinically significant and
most of the abnormal test results normalized during the
course of the study without further intervention. Impor-
tant is that no linear dose depending relationship
between the administration of ferroquine and increase
of liver parameters was observed in this study.
Based on previous animal and human studies showing
prolongation of the QT interval for chloroquine a spe-
cial emphasis was laid on the assessment of cardiac
effects [28-32]. Ferroquine itself has been shown to have
i nv i t r oe f f e c t so nh E R Gc h a n n e l s .T h e r ew a sa l s oa
trend toward changes in QTc interval parameters in tel-
emetered animals. The current findings show several
patients in the repeated dose study with T wave mor-
phology changes on their ECG readings following ferro-
quine administration, and most of the time associated
with U waves. These findings even though they are not
clinically significant highlight the potential of a cardiac
effect of ferroquine on humans.
Conclusions
In conclusion, ferroquine showed a favourable tolerabil-
ity and safety profile up to 1,600 mg when administered
as single dose, and appears to be well tolerated up to
800 mg once daily for three days. Although gastrointest-
inal disorders (including nausea and vomiting) and ner-
vous system disorders (including dizziness and
headache) appear to be the prevalent clinical adverse
events, the liver is the potential target organ and it
should be carefully monitored via liver function tests.
Ferroquine has the potential to prolong the QTc interval
and affect T wave morphology. Subjects should undergo
careful ECG monitoring while taking this investigational
product.
Acknowledgements
The authors wish to thank the participants, the chiefs of villages and the
inhabitants of Lambaréné and his surroundings. We thank the staff of the
Medical Research Unit of the Albert Schweitzer Hospital particularly
Philemon Koumba Koumba, Léonce Massoussa Mbadinga, Tatiana Nymane,
Virginie Mouteyi, Brigitte Migombet, Ariane Ntseyi, Anselme Nzengue, and
Ulrich Davy Kombila.
Author details
1Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon.
2Institute of Tropical Medicine, University of Tübingen, Germany.
3Département de Parasitologie-Mycologie, Faculté de Médecine, Université
des Sciences de la Santé, Libreville, Gabon.
4Sanofi-Aventis Research and
Development, Chilly-Mazarin, France.
5Department of Medicine I, Division of
Infectious Diseases and Tropical Medicine, Medical University of Vienna,
Austria.
Authors’ contributions
GMN carried out the safety study and drafted the manuscript. CS, MDB,
MAM, PBM, COS, BL carried out the study. MK, MR, PGK participated in the
design of the study and performed the statistical analysis. DTM and BL
conceived of the study, and participated in its design and coordination. All
authors read and approved the final manuscript.
Competing interests
Authors declare no conflict of interest. This study was funded by the
Department of Research of Sanofi-Aventis as part of the developing
programme of ferroquine. Part of this work was presented as dissertation by
GMN for his medical degree’s thesis at the Faculty of Medicine in Libreville,
Gabon, MK, PGK and BL were co-directors of the thesis (Université des
Sciences de la Santé (USS), Thesis n°524, 2006)
Received: 23 October 2010 Accepted: 1 March 2011
Published: 1 March 2011
References
1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Evidence of
artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008,
359:2619.
2. Biot C, Glorian G, Maciejewski LA, Brocard JS, Domarle O, Blampain G,
Millet P, Georges AJ, Abessolo H, Dive D, Lebibi J: Synthesis and
antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine
analogue. J Med Chem 1997, 40:3715-3718.
3. Biot C, Delhaës L, N’Diaye CM, Maciejewski LA, Camus D, Dive D, Brocard JS,
Dive D: Synthesis and antimalarial activity in vitro of potential
metabolites of ferrochloroquine and related compounds. Bioorg Med
Chem 1999, 7:2844.
4. Delhaës L, Abessolo H, Biot C, Berry L, Delcourt P, Maciejewski L, Brocard J,
Camus D, Dive D: In vitro and in vivo antimalarial activity of
ferrochloroquine, a ferrocenyl analogue of chloroquine against
chloroquine resistant malaria parasites. Parasitol Res 2001, 87:239-244.
5. Domarle O, Blampain G, Agnaniet H, Nzadiyabi T, Lebibi J, Brocard J,
Maciejewski L, Biot C, Georges AJ, Millet P: In vitro antimalarial activity of
a new organometallic analog, ferrocene-chloroquine. Antimicrob Agents
Chemother 1998, 42:540-544.
6. Atteke C, Ndong JM, Aubouy A, Maciejewski L, Brocard J, Lebibi J,
Deloron P: In vitro susceptibility to a new antimalarial organometallic
analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-
Ogooue region of Gabon. J Antimicrob Chemother 2003, 51:1021-1024.
7. Pradines B, Fusai T, Daries W, Laloge V, Rogier C, Millet P, Panconi E,
Kombila M, Parzy D: Ferrocene-chloroquine analogues as antimalarial
agents: in vitro activity of ferrochloroquine against 103 Gabonese
isolates of Plasmodium falciparum. J Antimicrob Chemother 2001,
48:179-184.
8. Pradines B, Tall A, Rogier C, Spiegel A, Mosnier J, Marrama L, Fusai T,
Millet P, Panconi E, Trape JF, Parzy D: In vitro activities of ferrochloroquine
against 55 Senegalese isolates of Plasmodium falciparum in comparison
with those of standard antimalarial drugs. Trop Med Int Health 2002,
7:265-270.
9. Grobusch MP, Lell B, Schwarz NG, Gabor J, Dörnemann J, Pötschke M,
Oyakhirome S, Kiessling GC, Necek M, Langin MU, Klouwenberg PK,
Klopfer A, Naumann B, Altun H, Agnandji ST, Goesch J, Decker M,
Salazar CL, Supan C, Kombila DU, Borchert L, Koster KB, Pongratz P,
Adegnika AA, Glasenapp I, Issifou S, Kremsner PG: Intermittent preventive
treatment against malaria in infants in Gabon–a randomized, double-
blind, placebo-controlled trial. J Infect Dis 2007, 196:1595-1602.
10. Ramharter M, Adegnika AA, Agnandji ST, Matsiegui PB, Grobusch MP,
Winkler S, Graninger W, Krishna J, Yazdanbakhsh M, Mordmueller B, Lell B,
Missinou MA, Mavoungou E, Issifou S, Kremsner PG: History and
perspectives of medical research at the Albert Schweitzer Hospital in
Lambaréné, Gabon. Wiener Klinische Wochenschrift/Middle European Journal
of Medicine 2007, 119(Suppl 3):8-12.
11. Dal-Bianco MP, Köster KB, Kombila UD, Kun JFK, Grobusch MP, Mombo-
Ngoma G, Matsiegui PB, Supan C, Ospina Salazar CL, Missinou MA, Issifou S,
Lell B, Kremsner PG: High Prevalence of Asymptomatic Plasmodium
falciparum Infection in Gabonese Adults. Am J Trop Med Hyg 2007, 77:939-942.
12. Borrmann S, Adegnika AA, Matsiegui PB, Issifou S, Schindler A, Mawili-
Mboumba DP, Baranek T, Wiesner J, Jomaa H, Kremsner PG:
Fosmidomycin-clindamycin for Plasmodium falciparum infections in
African children. J Infect Dis 2004, 189:901-908.
13. Chang C, Lin-Hua T, Jantanavivat C: Studies on a new antimalarial
compound: pyronaridine. Trans R Soc Trop Med Hyg 1992, 86:7-10.
Mombo-Ngoma et al. Malaria Journal 2011, 10:53
http://www.malariajournal.com/content/10/1/53
Page 10 of 1114. Mzayek F, Deng H, Mather FJ, Wasilevich EC, Liu H, Hadi CM, Chansolme DH,
Murphy HA, Melek BH, Tenaglia AN, Mushatt DM, Dreisbach AW, Lertora JJL,
Krogstad DJ: Randomized dose-ranging controlled trial of AQ-13, a
candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin
Trials 2007, 2:e6.oi:10.1371/journal.pctr.0020006.
15. Oyakhirome S, Issifou S, Pongratz P, Barondi F, Ramharter M, Kun JFK,
Missinou MA, Lell B, Kremsner PG: Randomized controlled trial of
fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the
treatment of Plasmodium falciparum malaria. Antimicrob Agents
Chemother 2007, 51:1869-1871.
16. Ramharter M, Noedl H, Thimasarn K, Wiedermann G, Wernsdorfer G,
Wernsdorfer WH: In vitro activity of tafenoquine alone and in
combination with artemisinin against Plasmodium falciparum. Am J Trop
Med Hyg 2002, 67:39-43.
17. Ramharter M, Oyakhirome S, Klein Klouwenberg P, Adégnika AA,
Agnandji ST, Missinou MA, Matsiégui PB, Mordmüller B, Borrmann S,
Kun JFK, Lell B, Krishna S, Graninger W, Issifou I, Kremsner PG: Artesunate-
clindamycin versus quinine-clindamycin in the treatment of Plasmodium
falciparum malaria: a randomized controlled trial. Clin Infect Dis 2005,
40:1777-1784.
18. Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Bélard S,
Schlie M, Kammer J, Koumba PK, Cisse B, Mordmüller B, Lell B, Issifou S,
Oeuvray C, Fleckenstein L, Kremsner PG: Fixed-dose pyronaridine-
artesunate combination for treatment of uncomplicated falciparum
malaria in pediatric patients in Gabon. J Infect Dis 2008, 198:911-919.
19. Wiesner J, Borrmann S, Jomaa H: Fosmidomycin for the treatment of
malaria. Parasitol Res 2003, 90(Suppl 2):s71-76, Review.
20. Baird JK: Effectiveness of antimalarial drugs. N Engl J Med 2005,
352:1565-1577.
21. Drugs for rheumatoid arthritis. Med Lett Drugs Ther 2000, 42:57-64.
22. Drugs for parasitic infections. Med Lett Drugs Ther 2004, 46:1-12.
23. McIntosh HM, Greenwood BM: Chloroquine or amodiaquine combined
with sulfadoxine-pyrimethamine as a treatment for uncomplicated
malaria–A systematic review. Ann Trop Med Parasitol 1998, 93:265-270.
24. Mying HY, Tipmanee P, Nosten F, Day NP, Pukrittayakamee S,
Looareesuwan S, White NJ: A systematic overview of published
antimalarial drug trials. Trans R Soc Trop Med Hyg 2004, 98:73-81.
25. Taylor WRJ, White NJ: Antimalarial drug toxicity: A review. Drug Safety
2004, 27:25-61.
26. White NJ: The treatment of malaria. N Engl J Med 1996, 335:800-806.
27. Avina-Zubieta JA, Galindo-Rodriguez G, Newman S, Suarez-Almazor ME,
Russell AS: Long-term effectiveness of antimalarial drugs in rheumatic
diseases. Ann Rheum Dis 1998, 57:583-587.
28. Benavides-Haro DE, Sanchez-Chapula JA: Chloroquine blocks the
background potassium current in guinea pig atrial myocytes. Arch
Pharmacol 2000, 361:311-318.
29. Bustos MD, Gay F, Diquet B, Thomare P, Warot D: The pharmacokinetics
and electrocardiographic effects of chloroquine in healthy subjects. Trop
Med Parasitol 1994, 45:83-86.
30. Clemessy JL, Favier C, Borron SW, Hantson PE, Vicaut E, Baud FJ:
Hypokalemia related to acute chloroquine ingestion. Lancet 1995,
346:877-880.
31. Riou B, Barriot P, Rimailho A, Baud FJ: Treatment of severe chloroquine
poisoning. N Engl J Med 1998, 318:1-6.
32. Sanchez-Chapula JA, Salinas-Stefanon E, Torres-Jacome J, Benavides-
Haro DE, Navarro-Polanco RA: Blockade of currents by antimalarial drug
chloroquine in feline ventricular myocytes. J Pharmacol Exptl Therapeutics
2001, 297:437-445.
doi:10.1186/1475-2875-10-53
Cite this article as: Mombo-Ngoma et al.: Phase I randomized dose-
ascending placebo-controlled trials of ferroquine - a candidate anti-
malarial drug - in adults with asymptomatic Plasmodium falciparum
infection. Malaria Journal 2011 10:53.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mombo-Ngoma et al. Malaria Journal 2011, 10:53
http://www.malariajournal.com/content/10/1/53
Page 11 of 11